Birdwatch Note
2025-02-15 20:07:00 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
China’s advancements in diabetes treatment are promising, their integration into U.S. medical practice depends on thorough validation through clinical trials and regulatory approval. The suggestion that financial motivations are hindering adoption lacks substantiated evidence. https://medium.com/%40thechinaacademy/chinas-diabetes-cure-america-s-last-hope-15f231cdaec6
Written by 869C696B7C07E093829A0B364FF12AA8FA76DCF2C60CB236F9298C34FAE4E35C
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1890493554637566120
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1890855351509221687
- noteId - 1890855351509221687
- participantId -
- noteAuthorParticipantId - 869C696B7C07E093829A0B364FF12AA8FA76DCF2C60CB236F9298C34FAE4E35C Participant Details
- createdAtMillis - 1739650020850
- tweetId - 1890493554637566120
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- China’s advancements in diabetes treatment are promising, their integration into U.S. medical practice depends on thorough validation through clinical trials and regulatory approval. The suggestion that financial motivations are hindering adoption lacks substantiated evidence. https://medium.com/%40thechinaacademy/chinas-diabetes-cure-america-s-last-hope-15f231cdaec6
Note Ratings
rated at | rated by | |
2025-02-16 15:18:39 -0600 | Rating Details | |
2025-02-16 14:59:00 -0600 | Rating Details | |
2025-02-16 14:01:44 -0600 | Rating Details | |
2025-02-16 12:23:43 -0600 | Rating Details | |
2025-02-16 11:19:19 -0600 | Rating Details | |
2025-02-16 10:14:16 -0600 | Rating Details | |
2025-02-16 10:00:20 -0600 | Rating Details | |
2025-02-16 09:34:33 -0600 | Rating Details | |
2025-02-16 09:30:41 -0600 | Rating Details | |
2025-02-16 09:28:54 -0600 | Rating Details | |
2025-02-16 09:02:39 -0600 | Rating Details | |
2025-02-16 08:14:00 -0600 | Rating Details | |
2025-02-16 07:15:57 -0600 | Rating Details | |
2025-02-16 07:04:34 -0600 | Rating Details | |
2025-02-16 05:31:23 -0600 | Rating Details | |
2025-02-16 04:18:19 -0600 | Rating Details | |
2025-02-16 03:22:30 -0600 | Rating Details | |
2025-02-16 03:13:19 -0600 | Rating Details | |
2025-02-16 02:17:34 -0600 | Rating Details | |
2025-02-16 02:03:05 -0600 | Rating Details | |
2025-02-16 00:57:35 -0600 | Rating Details | |
2025-02-15 22:01:44 -0600 | Rating Details | |
2025-02-15 21:28:20 -0600 | Rating Details | |
2025-02-15 19:56:53 -0600 | Rating Details | |
2025-02-15 17:21:00 -0600 | Rating Details | |
2025-02-15 16:12:04 -0600 | Rating Details | |
2025-02-15 15:23:40 -0600 | Rating Details | |
2025-02-15 14:45:34 -0600 | Rating Details | |
2025-02-15 14:25:17 -0600 | Rating Details | |
2025-02-18 09:38:14 -0600 | Rating Details | |
2025-02-18 02:56:24 -0600 | Rating Details | |
2025-02-18 00:05:41 -0600 | Rating Details | |
2025-02-17 08:54:44 -0600 | Rating Details | |
2025-02-16 23:29:38 -0600 | Rating Details | |
2025-02-16 23:11:44 -0600 | Rating Details | |
2025-02-16 20:17:33 -0600 | Rating Details | |
2025-02-16 11:18:54 -0600 | Rating Details | |
2025-02-16 09:16:02 -0600 | Rating Details | |
2025-02-16 09:06:59 -0600 | Rating Details | |
2025-02-16 07:58:05 -0600 | Rating Details | |
2025-02-16 07:53:55 -0600 | Rating Details | |
2025-02-16 06:24:55 -0600 | Rating Details | |
2025-02-16 04:32:32 -0600 | Rating Details | |
2025-02-16 03:33:30 -0600 | Rating Details | |
2025-02-16 03:18:22 -0600 | Rating Details | |
2025-02-16 02:01:47 -0600 | Rating Details | |
2025-02-15 22:00:55 -0600 | Rating Details | |
2025-02-15 20:39:49 -0600 | Rating Details | |
2025-02-15 20:08:20 -0600 | Rating Details | |
2025-02-15 20:07:32 -0600 | Rating Details | |
2025-02-15 17:55:26 -0600 | Rating Details | |
2025-02-15 15:16:19 -0600 | Rating Details | |
2025-02-17 14:45:07 -0600 | Rating Details | |
2025-02-17 10:54:11 -0600 | Rating Details | |
2025-02-16 23:43:39 -0600 | Rating Details | |
2025-02-16 22:44:39 -0600 | Rating Details | |
2025-02-16 10:12:13 -0600 | Rating Details | |
2025-02-16 09:21:18 -0600 | Rating Details | |
2025-02-16 08:13:05 -0600 | Rating Details | |
2025-02-16 07:55:01 -0600 | Rating Details | |
2025-02-16 07:42:53 -0600 | Rating Details | |
2025-02-16 07:39:48 -0600 | Rating Details | |
2025-02-16 05:56:55 -0600 | Rating Details | |
2025-02-16 03:31:16 -0600 | Rating Details | |
2025-02-16 03:09:26 -0600 | Rating Details | |
2025-02-16 01:35:28 -0600 | Rating Details | |
2025-02-15 23:08:33 -0600 | Rating Details | |
2025-02-15 22:07:41 -0600 | Rating Details | |
2025-02-15 21:45:32 -0600 | Rating Details | |
2025-02-15 19:22:55 -0600 | Rating Details | |
2025-02-15 14:21:47 -0600 | Rating Details |